Clínica Baviera (CBAV.MC) — PoorCharlie Research Report

Price ~€48 live quote

Market cap $1,083M ~16.0M shares; free float ~20%

Enterprise value N/A Net cash €57.4M (Q1 26)

Overall score 79 Strong · out of 100

Score breakdown

79/100

Strong

Moat

17/20

Europe's leading private ophthalmology chain. 154 clinics across 4 countries with established surgeon teams and brand recognition; private-pay (~83%) means CBAV sets prices, not government schedules. Demographic tailwind permanent and accelerating.

Management

15/20

Board-directed (no Anglo-style named CEO); execution is consistent — revenue CAGR ~15%, organic clinic expansion ~10+/yr, net cash building. AIER's 73% control is a permanent overhang on capital allocation.

Business risk

13/20

AIER take-private optionality is the structural top risk. UK turnaround still unproven (Q1 26 loss narrowed 36% — first credible data point). Germany rolled over (revenue +3%, EBITDA -6%). Germany tax inspection open.

Key ratios

18/20

ROIC 21.8% (5yr median 25.9%), ROE 41.7%, FCF margin 15.5% heading to ~18% as UK matures. SBC ~1.2% of FCF; net cash; GF Score 100/100 — the only perfect score in the universe.

Valuation

16/20

~19.8x FCF; ~5.0% FCF yield. Market prices ~10% FCF/share growth with 3% terminal vs FY25 +30% and 5yr CAGR ~18.9%. Base case fair value €57: +19%.

0–39 Poor 40–59 Weak 60–74 Average 75–89 Strong 90–100 Exceptional

One-line thesis: Own Europe's leading private ophthalmology chain — a structurally growing, demographically anchored, net-cash cash machine that compounds revenue at 15%+ per year — at a 16x FCF price that reflects neither the UK expansion optionality nor the full earning power of a maturing Spain.

Part 1

Business Overview

1.1Business Model

Pure-play ophthalmology (eye-care) chain operating across Spain, Germany, Italy, and the UK. Performs surgical and diagnostic eye procedures from a network of 154 clinics (Q1 2026): 91 Spain, 34 Germany (incl. 1 Vienna), 10 Italy, 19 UK.
Service lines: interventions (surgeries) ~91% of revenue — refractive (LASIK), cataract + IOL, presbyopia, retina, glaucoma, oculoplastics. Consultations ~4%. Other ophthalmological income ~5%.
Customer mix: ~83% private individuals (self-pay), ~16% insurance, ~1% public health. Private-pay dominance means CBAV sets prices — significant pricing power.
Hub-and-spoke network: satellite clinics (consultation, pre-op, post-op — low capital cost) feed surgical clinics (full operating capability). Patient capture is cheap; surgical capacity deployed only where volumes justify it.
Revenue recognition on percentage-of-completion basis (surgeries include post-operative follow-ups).
Parent — AIER Eye Hospital Group (Shenzhen: 300015.SZ) owns 73.23% via AIER Eye International (Europe). World's largest ophthalmology chain (900+ eye hospitals). Acquired the majority stake via tender offer Aug 2017.
Each intervention generates roughly €2,000–5,000+ depending on type and market. Cataracts affect virtually all people over 70; presbyopia begins at ~40–45; myopia rates rising in younger cohorts. Demand is semi-compulsory and grows with the aging population.

SourceCBAV-DOSSIER.md §1 ^[1]

1.2Revenue Sources

Service line	FY2025 (€M)	% of revenue	Note
Interventions (surgeries)	275.4	91%	Refractive, cataract, presbyopia, specialty
Consultations	11.1	4%	Initial exam and post-op monitoring
Other ophthalmological income	15.2	5%	Retina, glaucoma, specialist pathologies
Total revenue (FY2025)	301.8	100%	+14.9% YoY

Segment	Q1 26 revenue (€M)	YoY	EBITDA margin	Notes
Spain	58.6	+9%	35.9%	The engine; held margin despite 4 new clinic costs
Germany (incl. Vienna)	16.7	+3%	29.5%	Soft. EBITDA -6%. Weak laser among younger; macro drag
Italy	6.5	+6%	~19% (+2pp)	Maturing; mix shifting to direct patients
UK	5.2	+20%	n/m (loss narrowed 36%)	Laser volume +48%, intraocular +11%. “In line with the plans”
Total (Q1 2026)	87.0	+8.4%	30.3%	Net income +14.2%

Notes Q1 2026 net income +14% ran AHEAD of revenue +8% for the first time in two years — the inverse of FY2025 (rev +15%, NI +5%). The UK loss narrowing and Spain holding margin are the two pillars. Germany rolled over — the new watched item.

SourceCBAV-DOSSIER.md §1 & §2 · CNMV-1Q-2026-Resultados-ENG-1.pdf ^{[1] [3]}

1.3Key Performance Indicators

154 total clinics (Q1 2026): 91 Spain, 34 Germany, 10 Italy, 19 UK — up from 148 at YE25 (+6 net in Q1).
1,989 employees in Q1 2026 (avg FY25 1,861, FY24 1,705).
Revenue €87.0M Q1 2026, +8.4% YoY; FY2025 €301.8M, +14.9% YoY; 5yr revenue CAGR 18.8%.
EBITDA margin 30.3% Q1 2026; FY2025 EBITDA €84.5M.
Net income margin tracking €14.7M / €87.0M = ~16.9% in Q1 2026.
FCF/share €2.93 FY2025 (+30% YoY); 5yr FCF/share CAGR ~18.9%.
Net cash €57.4M at Q1 2026 end (+€15M in 90 days); cash & equivalents €64.8M; bank debt only €7.9M.
Dividend €1.57/share proposed flat for FY2025 (~61% payout ratio).
10-year stock return ~+30.6% annualised; 5yr +38.0%; 3yr +48.5% — the longest, most consistent compounding track record in the universe.

SourceCBAV-DOSSIER.md §2 & §8 · CBAV-earnings-analysis-FY2025.md ^{[1] [4]}

Part 2

Moat

2.1Industry Overview & Growth

Elective eye surgery is a high-ticket, largely private-pay procedure. Each intervention generates ~€2,000–5,000+ depending on type and market.
Aging-population tailwind: cataracts affect virtually all people over 70; presbyopia begins at ~40–45; myopia rates rising in younger cohorts.
Cataract surgery is the most commonly performed surgery in the developed world. Unlike discretionary refractive (LASIK) procedures, cataracts and presbyopia worsen until treated — demand is semi-compulsory.
Geographic mix: Spain 47M population, Germany 84M, Italy 59M, UK 67M. Over-65 cohort growing every year.
No technology substitution risk: surgery requires trained surgeons and physical clinics; barriers to replicating a 154-clinic network with surgeon teams and brand recognition across four countries are substantial.

SourceCBAV-DOSSIER.md §1 & §5 ^[1]

2.2Qualitative Competitor Analysis

Optical Express (UK)Tier 2

Dossier flags Optical Express as the named UK competitor. Stronger UK competition is one of the risks to the 185% UK revenue growth assumption embedded in the impairment test.

Private NHS-referral providers (UK)Tier 2

Different reimbursement dynamics in the UK could keep CBAV's UK ramp slower than expected. Q1 2026 trajectory (loss -36%, revenue +20%) is the first credible data point on the rebuild plan.

AIER Eye International (Europe)Parent

73.23% owner. Brings global clinical best practices and balance-sheet backing, but creates take-private optionality, controlling-shareholder dynamics, and likely keeps the €1.57/share dividend flat (61% payout) for cash extraction.

Long-tail local ophthalmologistsNiche

Single-clinic and small-chain ophthalmologists across Europe lack the scale, network, surgeon-team depth, marketing reach, and pricing power of a 154-clinic group. The barrier is the network, not the procedure.

SourceCBAV-DOSSIER.md §1 & §6 ^[1]

2.3Moat Analysis

Moat type	Strength	Evidence
Scale & clinical network	Strong	154 clinics in 4 countries; established surgeon teams; brand recognition. Barriers to replicating substantial.
Brand & trust (private-pay)	Strong	~83% self-pay mix means CBAV sets prices. Patients choose CBAV because of trust and outcomes, not insurer steering.
Demographic tailwind	Strong	Aging population in 4 large European markets; cataracts and presbyopia growing semi-compulsorily.
Operating leverage	Medium	Hub-and-spoke (satellite + surgical) drives capital efficiency. Spain 28% operating margin.
Switching costs	Medium	Once a patient has a successful procedure, they (and their family) return for further care.
Regulatory	Medium	Regulated healthcare. Spain dominant private model; UK reimbursement dynamics different. AIER ownership adds Spanish-CNMV oversight.

SourceCBAV-DOSSIER.md §1 & §5 ^[1]

2.4Additional Moat Considerations

Selected from the 26-item framework. Items shown are the strongest supporting points and the most material concerns for Clinica Baviera specifically.

YesDemographic tailwindAging Europe; cataracts +70yrs, presbyopia +40–45yrs

YesPricing power~83% self-pay; CBAV sets prices, not government

YesHigh-quality capital efficiencyROIC 21.8% (5yr median 25.9%), ROE 41.7%

YesStrong organic growth5yr revenue CAGR 18.8%, FY25 +14.9%

YesOwner earnings ≈ reported FCFSBC just ~1.2% of FCF

YesFortress balance sheetNet cash €57.4M; bank debt only €7.9M

YesNo technology substitutionProcedure requires trained surgeons and physical clinics

YesMission-critical serviceCataract/presbyopia worsen until treated — semi-compulsory

ModPredictability of revenueRefractive (LASIK) is discretionary — cyclical in recession; cataract offsets

ModGeographic diversificationSpain 68%, Germany 20%, Italy + UK 12% — reducing but UK + Italy still loss-making

NoMajority-shareholder optionalityAIER 73.23% — structural; take-private risk on a depressed price

NoSmall-cap liquidityFree float ~20% post-2025 secondary; thin liquidity caps position size

NoDividend payout influenced by parent~61% payout; AIER influence keeps it elevated vs reinvest-all

SourceCBAV-DOSSIER.md §6 · Meta analysis from poorcharlie.io.txt (framework) ^{[1] [6]}

Part 3

Management

3.1Leadership & Tenure

Board-directed model. The Board of Directors consists of 7 members (5 male, 2 female) as of 31 December 2025. CBAV does not publicly name a “CEO” in the Anglo-Saxon sense; operational leadership is board-directed.
Controlling shareholder block: AIER Eye International (Europe) S.L.U. holds 73.23% (11,938,089 shares of 16,307,580) and Vito Gestión Patrimonial, S.L. holds 6.83% — combined 80.06% controlling block. No other 5%+ holders disclosed.
Recent block reduction: on 3 April 2025 AIER + Vito placed 1,304,606 shares (~8.00% of capital) via accelerated bookbuilding to qualified investors. AIER stake stepped down from 78.23% → 73.23%, Vito from 9.80% → 6.83%. Free float effectively doubled.
Board change FY25: only one board change in 2025 — Carolina Martínez-Caro appointed 6 November 2024 replacing Isabel Aguilera Navarro at end of statutory 4-year term. No other rotations.
Total board + senior management remuneration: €2,971k in 2025 (vs €2,338k in 2024, +27% YoY). Nine senior managers (Alta Dirección) plus 7 board members. No pension obligations, no termination indemnities for executive director contract.
Equity comp: 24 May 2024 board approved share-option plan for directors and physicians: 163,043 options granted, strike €23, exercise window 2027, total Black-Scholes fair value €1.645M (volatility 30%, risk-free 3%, share price at grant €29). Vesting requires continued employment to delivery date. Treasury buyback (293,087 shares purchased from AIER + Vito at €29.10 in 2024) funds the plan obligation; treasury = 289,066 shares (1.77% of capital) at 31 Dec 2025.
Individual director stakes not separately disclosed in CCAA 2025 — Spanish reporting threshold (3% / 5%) only captures AIER and Vito at year-end. Directors’ transactions disclosed as compliant: no unusual / relevant transactions in 2025 or 2024.
CBAV does not hold public earnings calls or issue quarterly guidance — explicit executive quotes are sparse. Strategy is reconstructed from management reports (Informe de Gestión).
The strategic narrative: “selective, sustained, disciplined” organic clinic expansion — infill cities first, preserve utilisation, then new cities.

SourceCBAV-DOSSIER.md §3 · Cuentas-anuales-consolidadas-e-individuales-inversores 2025.pdf Notas 13, 21, 23, 24 ^{[1] [2]}

3.2M&A History

Year	Target / action	Strategic role	Outcome
2017	AIER tender offer (majority stake)	Chinese parent acquires 73%+ control	Structural — permanent overhang
H2 2024	Eye Hospital Group / Optimax (UK)	19 UK clinics; entry into Europe's second-largest healthcare market	Loss-making, integration ongoing
FY2024	UK purchase price ~€11.1M (investment outflow)	Initial acquisition cost	Plus ongoing integration costs
May 2024	Buyback program initiated (up to 2% of capital)	Funded employee incentive / staff share program	Dilution management, not capital return at scale
Apr 2025	Secondary offering (AIER sold 8%)	Brought free float from ~12% to ~20%	Liquidity improved gradually
FY2025	11 new clinic openings (6 Spain, 2 Germany, 2 Italy, 1 UK)	Organic expansion	Multi-year ~10+/year pace consistent
Q1 2026	+6 net new clinics (4 Spain, 2 Germany)	Consistent ~10–15/yr pace	On track

Track record Acquisitions are infrequent and modest in scale. Growth is overwhelmingly organic. The UK acquisition is the live integration test; AIER's arrival is a permanent capital-allocation overhang.

SourceCBAV-DOSSIER.md §3 & §6 ^[1]

3.3Said vs Delivered

What management said / committed	When	What actually happened	Consistent?
Revenue growth ~15% per year as core strategy	Multi-year	5yr revenue CAGR 18.8%; FY2025 +14.9%	Yes — delivered consistently
Spain is the profit engine; group margin depends on it	FY2024+	Spain operating profit €57.2M (+20.2%); group margin only -1.1pp despite UK losses	Yes — Spain held the group together
UK acquisition integration will take time; losses expected	H2 2024	UK contributed to -€7.8M loss in “Rest of Europe”, FY2025	Yes — telegraphed
UK target ~185% revenue growth by 2029	FY2024 impairment test	Q1 26: revenue +20%, loss narrowed 36%, mgmt “in line with the plans”	In progress — positive Q1 data point
€1.57/share dividend annually	FY24 AGM	€1.57/share paid FY2025; €1.57/share proposed FY25 results	Yes — flat nominal
Organic clinic expansion ~10/yr	Implicit 5yr trend	FY2025 11 net; FY2024 ~17 (incl. UK); multi-year average consistent	Yes
Germany is a stable, cash-generative market	Multi-year	FY2025 rev +7.1%, EBITDA stable. Q1 26: rev +3%, EBITDA -6%	Watching — may have rolled over
Net cash position improves as FCF exceeds dividends + capex	FY24	FY25: €30.5M→€42.4M. Q1 26: → €57.4M (+€15M in 90 days)	Yes — over-delivered
Germany tax inspection: no material impact expected	FY25 notes	Inspection ongoing; directors state no material impact	Monitor resolution

Verdict Management executes on the stated playbook with consistency. Q1 2026: UK now showing positive operational trajectory (loss narrowing 36%, revenue +20%); Germany is the new watched item with revenue +3% and EBITDA -6%. Net cash building faster than the FY2025 pace. Two-front watching: (a) UK reaches breakeven by FY2027? (b) Germany recovers or rolls over?

SourceCBAV-DOSSIER.md §4 · CNMV-1Q-2026-Resultados-ENG-1.pdf ^{[1] [3]}

Part 4

Key Ratios

4.1Growth Rates

Metric	1Y	3Y CAGR	5Y CAGR	10Y CAGR
FCF Growth (Per Share) %	30%	6.60%	10.30%	27.60%
Revenue Growth (Per Share) %	14.80%	15.70%	18.80%	14.20%
EPS without NRI Growth %	8.50%	12.30%	21.70%	24%

FCF reaccelerating 1Y FCF/share +30% sits well above the 3Y CAGR 6.6% and 5Y 10.3% — the dip in 2023–24 (UK build-out drag) is reversing as Spain compounds and UK losses narrow.

Revenue compounding above 15% Revenue/share 14.8% (1Y) and 18.8% (5Y CAGR) are both strong — consistent high-teens organic + clinic expansion is the structural growth signal, regardless of which year of capex you read.

SourcePortfolio snapshot 30.05.2026.txt (GuruFocus export) ^[8]

4.2Margins

Metric	Current	5Y Growth Rate	5Y Median
Gross Margin %	n/a	0.30%	N/A
Operating Margin %	20.09%	2.10%	21.22%
FCF Margin %	15.52%	N/A	15.62%

Margins stable, not expanding Operating margin 20.09% (5Y median 21.22%) and FCF margin 15.52% (5Y median 15.62%) sit slightly below trend — the UK loss drag and Germany softness keep margins in the “OK” band while Spain runs at 36% EBITDA margin underneath.

SourcePortfolio snapshot 30.05.2026.txt ^[8]

4.3Capital Efficiency

Metric	Current	5Y Median
ROIC %	21.80%	25.93%
ROCE %	36.24%	39.71%
ROE %	41.72%	45.44%
Cash Conversion Ratio	1.11	1.11

ROIIC % (Return on Incremental Invested Capital)

Period	ROIIC %
1-Year	8.58%
3-Year	12.95%
5-Year	25.34%

ROE 41.7% with clean cash conversion ROE 41.72% (5Y median 45.44%) is elite, ROCE 36.24% strong, and cash conversion 1.11 confirms reported profit is genuinely cash — not a leveraged-return illusion.

ROIC compression from UK ROIC 21.80% vs 5Y median 25.93% — still strong but ~4pp below trend. ROIIC 1Y 8.58% and 3Y 12.95% mark the UK build-out era. The 5Y ROIIC 25.34% says the historical reinvestment economics are intact; the question is whether UK matures back into that band.

SourcePortfolio snapshot 30.05.2026.txt ^[8]

4.4Balance Sheet Health

Metric	Current
Debt-to-Equity	0.64
Cash-to-Debt	0.71
Interest Coverage	51.04
Current Ratio	0.97

Current ratio 0.97 is optical Current ratio just below 1.0 looks stretched on paper, but CBAV runs net cash €57.4M with interest coverage 51x and cash/debt 0.71 reflecting IFRS-16 lease liabilities — not financial leverage. No real liquidity concern.

SourcePortfolio snapshot 30.05.2026.txt ^[8]

4.5Shareholder Returns & Other Metrics

Metric	Current
1-Year Dividend Growth Rate (Per Share) %	N/A
3-Year Dividend Growth Rate (Per Share) %	N/A
Dividends per Share (TTM)	€1.57
1-Year Share Buyback Ratio	N/A
3-Year Share Buyback Ratio	0.60
5-Year Share Buyback Ratio	0.40
Goodwill-to-Asset %	0.12
Stock Based Compensation (mm)	0
Free Cash Flow (mm)	€46.83M

Clean shareholder math SBC zero, goodwill/asset 0.12 (modest, no acquisition risk), 3Y buyback ratio +0.60 and 5Y +0.40 mean float is shrinking even before the €1.57/share dividend — correct capital return for a 73%-controlled, growing business.

SourcePortfolio snapshot 30.05.2026.txt ^[8]

Part 5

Valuation

5.1Current Multiples vs 10-Year Context

Multiple	Current	10yr median	Read
P / FCF	19.8x	12.9x	Above median — quality re-rate
EV / FCF	19.3x	—	Net cash narrows EV slightly
EV / EBIT	15.0x	—	Reasonable for the ROIC
P / E (no NRI)	22.1x	—	Full but not stretched
FCF Yield	5.04%	—	Attractive given quality

SourcePortfolio snapshot 30.05.2026.txt ^[8]

5.2Reverse DCF — What the Market Prices In

Two-stage model, 10% discount rate, 20-year explicit. Current price ~€48.

Stage	Growth rate	Terminal	Implied fair value
Conservative	8%	2%	~€38
Market implied (~current)	10%	3%	~€48
Mid	12%	3%	~€57
High	15%	3%	~€75

What this means The market is pricing ~10% FCF/share growth with 3% terminal. FY2025 FCF/share +30% and 5yr CAGR ~18.9% are well above. The 30% FY2025 jump partly reflects a low FY2024 base (UK acquisition cash hit FY2024). A sober normalised estimate is ~12–15% — implying ~€57–75 fair value and a ~15–55% margin of safety. ROIC vs cost-of-capital spread of ~1,200bp compounds for another decade and is not fully priced in.

SourceCBAV-DOSSIER.md §8 ^[1]

5.3DCF Scenarios

Scenario	Growth yrs 1–10	Terminal	Fair value	vs ~€48
Market implied	10%	3%	~€48	—
Bear	8%	2%	~€38	-21%
Base	12%	3%	~€57	+19%
Bull	15%	3%	~€75	+56%

Asymmetry At ~19.8x FCF the market is pricing 10% growth from a business that delivered +30% FCF/share in FY2025 and compounded ~18.9% over five years. Bear case fair value €38 (8% growth): -21%. Base case fair value €57 (12% growth): +19%. Bull case fair value €75 (15% growth): +56%. ROIC of 22% on a ~10% cost of capital is a ~1,200bp spread that compounds — not fully reflected in price.

SourceCBAV-DOSSIER.md §8 ^[1]

Part 6

Risks

6.1Red flags, ranked by severity

Majority shareholder dynamics — AIER take-private optionalitySeverity: high (structural). AIER Eye International (Europe) owns 73.23%. Take-private risk: AIER can launch a tender offer to delist at any time; a low-ball offer at a depressed price would harm minority holders. Capital allocation influence: the flat €1.57/share dividend (~61% payout) likely reflects AIER's preference for cash extraction. Free float ~20% even after the April 2025 secondary — thin liquidity caps position size.
UK turnaround unproven; Italy still loss-makingSeverity: medium-high. Rest of Europe segment (Italy + UK) lost €7.8M in FY2025 on €38M revenue. Most is the UK (19 clinics, acquired H2 2024). Management's impairment-test assumption is 185% UK revenue growth by 2029 — ambitious. Q1 2026 first credible data point: UK revenue +20%, loss narrowed 36%. -€7.8M against €60.5M group operating profit = 12.9% absorbed; manageable now, material if it worsens. Breakeven target: ideally FY2027.
Dividend payout 61% — AIER-influenced capital allocationSeverity: medium. CBAV paid €26.4M (€1.57/share) on €42.1M net profit in FY2025 = ~63% payout. For a business reinvesting at 22% ROIC, retaining more capital would be value-additive — but AIER's influence keeps the payout elevated. Partial offset: CBAV still reinvests ~€30M/year in capex and net cash kept building. Verify the Spanish withholding rate applicable to the Icelandic LLC structure (standard 19%, treaty rates may differ).
Germany rolled over — new watched itemSeverity: medium. Q1 2026 Germany revenue +3%, EBITDA -6%. Adverse macro in industrial regions plus weak laser among younger price-sensitive customers. If Germany stays in negative-EBITDA-growth territory through H1 2026, it joins UK as a second drag and group margin could compress further.
Operating margin compression (21.2% → 20.1%)Severity: medium. Primarily investment-driven (UK losses + headcount for expansion) rather than competitive or structural. Spain's segment margin actually improved. A sub-18% operating margin would signal something more concerning.
Germany tax inspection (2019–2021) — unresolvedSeverity: low-medium. Care Vision GmbH under VAT, corporate tax, and business tax inspection. Management states no material impact expected. Routine on the face of it — but undisclosed risk until closed. Watch for resolution in FY2026 filing.
Refractive surgery cyclicalitySeverity: low. Laser refractive segment is economically sensitive (linked to consumer confidence). In a recession, patients defer LASIK. Mitigated by growing share of cataract/presbyopia (non-deferrable) and aging demographics.

SourceCBAV-DOSSIER.md §6 ^[1]

Verdict

Hold · consider adding on a real pullback

Stance: Hold. ~19.8x FCF; base case (12% growth) fair value €57: +19%. Quality compounder bought at a reasonable price; do not add here but do not sell. Q1 2026 confirmed the FY2025 thesis: UK loss narrowing materially, net income growing ahead of revenue, balance sheet building cash fast.
Add zone: A real pullback that opens 25%+ implied MoS — broadly low-€40s and below. Add cautiously given small-cap liquidity.
Trim trigger: AIER tender-offer announcement at a depressed price; UK loss widening through FY2026; group operating margin falling sub-18%; sustained Germany rev / EBITDA decline through H1 2026.
Watching: UK FY2027 breakeven trajectory (priority 1, Q1 26 first positive data point); Germany rev/EBITDA (new watched item); Spain growth above 8% danger threshold; FCF/share TTM convergence toward 15%+; AIER stake changes; Germany tax inspection resolution; FY25 dividend amount at May AGM.
Next review: H1 2026 results — expected July/August 2026.

Last reviewed May 29, 2026 after Q1 2026 results · Next review Jul/Aug 2026 (H1 2026)

References

Where every claim came from

[1]Company information/Clinica Baviera/CBAV-DOSSIER.mdLiving research-report source file, last updated 2026-05-29. Primary reference for all qualitative and quantitative content unless otherwise noted.
[2]Company information/Clinica Baviera/Cuentas-anuales-consolidadas-e-individuales-inversores 2025.pdfFY2025 consolidated annual accounts — primary source for FY2025 segment results, balance sheet, dividend.
[3]Company information/Clinica Baviera/CNMV-1Q-2026-Resultados-ENG-1.pdfCNMV Q1 2026 consolidated results (quarter ended 31 March 2026, published 27 May 2026) — primary source for Q1 2026 segment data, net cash, clinic count, narrative.
[4]Company information/Clinica Baviera/CBAV-earnings-analysis-FY2025.mdInternal FY2025 earnings analysis with segment commentary and FCF/share trend.
[5]Company information/Clinica Baviera/Paquete_TOTAL_CCAA_consolidadas_e_individuales_2024_para_web.pdf & Compilacion-para-web-inversores 2023.pdfFY2024 and FY2023 consolidated accounts — multi-year revenue, EBITDA, FCF, clinic count history.
[6]Stock portfolio/Meta analysis from poorcharlie.io.txtScoring framework and 26-item additional-moat checklist; used for the structure of Part 2.4 only, not for CBAV-specific content.
[7]Company information/Clinica Baviera/Full-Compilation-Financiera-2022.pdf & Informe-financiero-2020-CB-Comprimido_compressed31.pdf & CCAA-2019-CNMV.pdfFY2022, FY2020, FY2019 historical accounts — used for 5-year FCF/share CAGR and revenue history.
[8]Stock portfolio/Portfolio snapshot 30.05.2026.txtGuruFocus portfolio snapshot exported 2026-05-30; primary source for Part 4 ratios.

This is one of three free sample reports.
Members get the full research universe: all 47 today, growing to 80, with quarterly updates after every earnings release.

See access plans

Clínica Baviera (Grupo Baviera)

Business Overview

1.1Business Model

1.2Revenue Sources

1.3Key Performance Indicators

Moat

2.1Industry Overview & Growth

2.2Qualitative Competitor Analysis

2.3Moat Analysis

2.4Additional Moat Considerations

Management

3.1Leadership & Tenure

3.2M&A History

3.3Said vs Delivered

Key Ratios

4.1Growth Rates

4.2Margins

4.3Capital Efficiency

ROIIC % (Return on Incremental Invested Capital)

4.4Balance Sheet Health

4.5Shareholder Returns & Other Metrics

Valuation

5.1Current Multiples vs 10-Year Context

5.2Reverse DCF — What the Market Prices In

5.3DCF Scenarios

Risks

6.1Red flags, ranked by severity

Hold · consider adding on a real pullback

Where every claim came from